Jens Hennecke is a molecular biologist by training and has 15 years of business and deal-making track record in the biopharmaceutical industry. Before joining SOTIO as Chief Business Officer, he had his own business consulting firm and has been serving as an advisor for business and corporate development for various European biotech companies since 2012. Until 2012, Jens was Senior Vice President Business Development and a member of the executive management team of Nasdaq-listed Micromet, Inc. At Micromet, he was responsible for business development, alliance management, intellectual property and other operational functions. During his 12 years tenure at Micromet, Jens closed corporate deals and managed the alliances with multiple large pharma companies on Micromet’s T cell engager BiTE platform and products, and has been instrumental in the $1.2 billion acquisition of Micromet by Amgen in 2012. Prior to joining Micromet in 2001, Jens received a diploma in biology from the University of Göttingen, Germany, and completed his Ph.D. thesis at the ETH Zürich, Switzerland. He also carried out post-doctoral research at Harvard University.

 Biopharmacology